Abstract library

48 results for "calcitonin".
#1472 Neuroendocrine Pancreatic Tumors Secreting Calcitonin
Introduction: Neuroendocrine Pancreatic Tumors (NPT) secreting calcitonin are rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Valbona Liço
Keywords: calcitonin
#333 Sporadic Hypercalcitoninemia: Thyroid Medullary carcinoma, Autoimmune Thyroiditis or GLP-1 Agonists’ Effect?
Introduction: Glucagon-like peptide 1 (GLP-1) receptor agonists’ stimulated C-cell hyperplasia and tumors in rodents, but not in humans. Calcitonin also increased in autoimmune thyroid disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Raluca A. Trifanescu
#1040 TIM16 Inhibition Decreases Calcitonin Secretion and Enhances Sensitivity to Paclitaxel in a Human Medullary Thyroid Carcinoma Cells
Introduction: TIM 16 protein is part of the traslocase complex TIM 23 situated in the mitochondrial inner membrane, encoded by the Magmas gene, that is overexpressed in several tumors. Magmas silencing causes a greater sensitivity to apoptotic stimuli. We recently demonstrated that, in a human medullary thyroid carcinoma cell line (TT), compound 5, a TIM 16 inhibitor, was not cytotoxic but enhanced the proapoptotic effects of staurosporine
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Teresa Gagliano
#1081 High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?
Introduction: Thyrocalcitonin (TCT) is usually associated with medullary thyroid cancer. However, some neuroendocrine tumors (NETs) have also high serum TCT levels.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Thomas Walter
Keywords: thyrocalcitonin
#1658 The Clinical Significance of Elevated Serum Procalcitonin in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: Elevated serum procalcitonin (PCT) was reported in some patients with neuroendocrine neoplasms (NEN), but its clinical significance in gastroenteropancreatic NEN (GEP-NEN) was still unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Jie Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...
#48 Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for about 5-10% of all thyroid cancers, and while disease localized to the thyroid can be cured by surgery, there is no effective treatment for disseminated MTC. Constitutive activation of the RET proto-oncogene is implicated in familial and a proportion of sporadic cases, and up-regulates the AKT/PI3-kinase/mTOR signal transduction pathway. Recent studies have shown that the inhibitor of mTOR, everolimus (RAD001, Novartis, Basel), can inhibit the proliferation of the TT cell line and human MTC tumor cells in vitro. Clinically, everolimus has been shown to attenuate the progression of some gastrointestinal neuroendocrine tumors, but its clinical use in MTC has not yet been evaluated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Maralyn R Druce
#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
#767 Pancreatic NET Tumors Presenting with Hypercalcitonemia
Introduction: Pancreatic neuroendocrine tumors (pNET) secrete a variety of hormones, but calcitonin secretion rarely occurs.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Kalliopi Pazaitou-Panayiotou
#915 Thyroid Disturbances in Neuroendocrine Tumors: A Romanian Retrospective Study
Introduction: For the last decades, neuroendocrine tumors (NETs) was a large area of investigation.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Mara Carsote
#125 Ectopic hormone secreting phaeochromocytoma: A francophone observational study
Introduction: Ectopic hormone-secreting phaeochromocytomas are rare and only small reports of 1-2 cases exist in the literature. In the past, this condition has been linked with increased malignancy, familial syndromes and ACTH secretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Bruno Carnaille
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.